Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination.

Madsen A, Azimi L, Tete S, Zhou F, Krammer F, Cox RJ, Jul-Larsen Å.

Vaccine X. 2019 Jun 20;2:100029. doi: 10.1016/j.jvacx.2019.100029. eCollection 2019 Aug 9.

2.

Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study.

Trieu MC, Jul-Larsen Å, Sævik M, Madsen A, Nøstbakken JK, Zhou F, Skrede S, Cox RJ.

Clin Infect Dis. 2019 Jan 18;68(3):382-392. doi: 10.1093/cid/ciy487.

3.

Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.

Tete SM, Jul-Larsen Å, Rostami S, Lunde THF, Søland H, Krammer F, Cox RJ.

Vaccine. 2018 Apr 12;36(16):2213-2219. doi: 10.1016/j.vaccine.2018.02.022. Epub 2018 Mar 13.

PMID:
29548607
4.

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.

Olberg HK, Eide GE, Cox RJ, Jul-Larsen Å, Lartey SL, Vedeler CA, Myhr KM.

Eur J Neurol. 2018 Mar;25(3):527-534. doi: 10.1111/ene.13537. Epub 2018 Jan 6.

PMID:
29205701
5.

Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.

Islam S, Mohn KG, Krammer F, Sanne M, Bredholt G, Jul-Larsen Å, Tete SM, Zhou F, Brokstad KA, Cox RJ.

Vaccine. 2017 Oct 9;35(42):5666-5673. doi: 10.1016/j.vaccine.2017.08.044. Epub 2017 Sep 9.

PMID:
28899626
6.

Long-term Maintenance of the Influenza-Specific Cross-Reactive Memory CD4+ T-Cell Responses Following Repeated Annual Influenza Vaccination.

Trieu MC, Zhou F, Lartey S, Jul-Larsen Å, Mjaaland S, Sridhar S, Cox RJ.

J Infect Dis. 2017 Mar 1;215(5):740-749. doi: 10.1093/infdis/jiw619.

PMID:
28007925
7.

Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.

Manenti A, Tete SM, Mohn KG, Jul-Larsen Å, Gianchecchi E, Montomoli E, Brokstad KA, Cox RJ.

Vaccine. 2017 Jan 3;35(1):191-198. doi: 10.1016/j.vaccine.2016.10.024. Epub 2016 Oct 24.

8.

Live Attenuated Influenza Vaccine in Children Induces B-Cell Responses in Tonsils.

Mohn KG, Brokstad KA, Pathirana RD, Bredholt G, Jul-Larsen Å, Trieu MC, Lartey SL, Montomoli E, Tøndel C, Aarstad HJ, Cox RJ.

J Infect Dis. 2016 Sep 1;214(5):722-31. doi: 10.1093/infdis/jiw230. Epub 2016 May 30. Erratum in: J Infect Dis. 2016 Oct 3;:.

9.

Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients.

Eagan TM, Hardie JA, Jul-Larsen Å, Grydeland TB, Bakke PS, Cox RJ.

Respir Med. 2016 Jun;115:53-9. doi: 10.1016/j.rmed.2016.04.008. Epub 2016 Apr 20.

10.

Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway.

Mohn KG, Cox RJ, Tunheim G, Berdal JE, Hauge AG, Jul-Larsen Å; Norwegian Pandemic Group, Peters B, Oftung F, Jonassen CM, Mjaaland S.

PLoS One. 2015 Nov 25;10(11):e0143281. doi: 10.1371/journal.pone.0143281. eCollection 2015.

11.

Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations.

Eidem S, Tete SM, Jul-Larsen Å, Hoschler K, Montomoli E, Brokstad KA, Cox RJ.

Vaccine. 2015 Aug 7;33(33):4146-54. doi: 10.1016/j.vaccine.2015.05.081. Epub 2015 Jun 7.

PMID:
26057137
12.

Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.

Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ.

Hum Vaccin Immunother. 2015;11(7):1654-62. doi: 10.1080/21645515.2015.1048939.

13.

Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.

Pedersen GK, Sjursen H, Nøstbakken JK, Jul-Larsen Å, Hoschler K, Cox RJ.

Hum Vaccin Immunother. 2014;10(8):2408-16. doi: 10.4161/hv.29583.

14.

An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Krammer F, Jul-Larsen A, Margine I, Hirsh A, Sjursen H, Zambon M, Cox RJ.

Clin Vaccine Immunol. 2014 Aug;21(8):1153-63. doi: 10.1128/CVI.00272-14. Epub 2014 Jun 18.

15.

A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.

Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen Å, Guzmán CA, Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinchcliffe M, Cox RJ.

Influenza Other Respir Viruses. 2013 Nov;7(6):1181-93. doi: 10.1111/irv.12056. Epub 2012 Nov 21.

16.

The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.

Jul-Larsen Å, Madhun AS, Brokstad KA, Montomoli E, Yusibov V, Cox RJ.

Hum Vaccin Immunother. 2012 May;8(5):653-61. doi: 10.4161/hv.19503. Epub 2012 May 1.

17.

The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.

Svindland SC, Jul-Larsen Å, Pathirana R, Andersen S, Madhun A, Montomoli E, Jabbal-Gill I, Cox RJ.

Influenza Other Respir Viruses. 2012 Mar;6(2):90-100. doi: 10.1111/j.1750-2659.2011.00271.x. Epub 2011 Jul 12.

18.

Subcellular distribution of nuclear import-defective isoforms of the promyelocytic leukemia protein.

Jul-Larsen A, Grudic A, Bjerkvig R, Bøe SO.

BMC Mol Biol. 2010 Nov 21;11:89. doi: 10.1186/1471-2199-11-89.

19.

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.

Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, Nilsen M, Mohn K, Jul-Larsen A, Smith I, Major D, Wood J, Cox RJ.

Vaccine. 2010 Dec 16;29(2):266-73. doi: 10.1016/j.vaccine.2010.10.038. Epub 2010 Oct 27.

PMID:
21034828
20.

Cell-cycle regulation and dynamics of cytoplasmic compartments containing the promyelocytic leukemia protein and nucleoporins.

Jul-Larsen A, Grudic A, Bjerkvig R, Bøe SO.

J Cell Sci. 2009 Apr 15;122(Pt 8):1201-10. doi: 10.1242/jcs.040840.

21.

Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres.

Grudic A, Jul-Larsen A, Haring SJ, Wold MS, Lønning PE, Bjerkvig R, Bøe SO.

Nucleic Acids Res. 2007;35(21):7267-78. Epub 2007 Oct 24.

22.

Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.

Bøe SO, Haave M, Jul-Larsen A, Grudic A, Bjerkvig R, Lønning PE.

J Cell Sci. 2006 Aug 15;119(Pt 16):3284-95. Epub 2006 Jul 25.

23.

PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication.

Jul-Larsen A, Visted T, Karlsen BO, Rinaldo CH, Bjerkvig R, Lønning PE, Bøe SO.

Exp Cell Res. 2004 Aug 1;298(1):58-73.

PMID:
15242762

Supplemental Content

Loading ...
Support Center